Curis reports Q1 2026 net loss and provides business update

Curis reported a Q1 2026 net loss of $24.2 million, or $1.25 per share, an increase from the prior year. Research and development expenses decreased due to lower employee and manufacturing costs, while general and administrative expenses rose due to financing costs. The company has $15 million in cash, with potential for more from warrant exercises. Curis expects its cash and anticipated proceeds to fund operations into the second half of 2027. The company is progressing with its lymphoma and leukemia studies, with data updates expected in 2027.